Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25255898 | 0.83 | SCD5 (0.38) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL159379 | 0.81 | GABRP (0.43) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL25261953 | 0.81 | HTT (0.43) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL25253389 | 0.81 | KDM4E (0.43) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL30394540 | 0.79 | DDB1 (0.46) | KDM4EKMT2A | |
| SCHEMBL255458 | 0.79 | DDB1 (0.46) | KDM4EKMT2A | |
| SCHEMBL23453444 | 0.78 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2 | |
| SCHEMBL25257655 | 0.77 | SMN1; SMN2 (0.40) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL23211825 | 0.77 | SLC6A2 (0.43) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL26666921 | 0.77 | HRH3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3856737-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064792-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-02 | — | — | WO | disclosed |
| US-9249123-B2 | Pyridinones/pyrazinones, method of making, and method of use thereof | GENENTECH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2611790-B1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| CN-103313987-A | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| EP-2611790-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, PDXK, TYK2 | NAPRT 1435/4885KDM4E 2138/4885GLA 3443/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | NAPRT 1454/4885KDM4E 325/4885GLA 2621/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | NAPRT 1454/4885KDM4E 325/4885GLA 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.